MADRIGAL PHARMACEUTICALS, INC. 4

Director Richard S. Levy received equity compensation awards of 454 RSUs and stock options for 766 shares of Madrigal Pharmaceuticals, Inc. common stock on June 17, 2026.

On June 17, 2026, Richard S. Levy, a director of Madrigal Pharmaceuticals, Inc., received a routine equity compensation package consisting of 454 restricted stock units (reported as Common Stock) that will vest in full on the earlier of June 17, 2027 or the 2027 annual stockholders’ meeting, and a stock option grant for 766 shares of Common Stock at an exercise price of $499.86 per share, vesting on the same schedule. These awards increased his direct beneficial ownership to 22,469 shares of Common Stock and 766 stock options, with no shares sold or purchased for cash in the open market. Based on the option exercise price as a proxy for current value, the RSU grant is worth approximately $227,940 and the option grant has a notional underlying value of about $382,900, bringing the estimated value of his post-transaction equity holdings (shares plus option underlying) to roughly $11.7 million.

Filing Facts

CIK

1157601

Ticker

MDGL

Form

4

Source Type

sec

Accession

0001628280-26-044340

Alert Tier

5